Novel target sites in bacteria for overcoming antibiotic resistance.
Resistance to marketed antibiotics continues to increase. During the last 10 years some 200 bacterial genome sequences have become available, giving rise to expectations that genomics would provide a plethora of novel targets and hence a flood of new therapeutic agents. Contrary to some predictions the genomic effort has yet to yield a substantial number of novel class agents in clinical development. What are the reasons for the differences between expectations and reality? This article reviews what has been achieved in the exploitation of bacterial genomes for the discovery of novel antibacterials.
Black
Michael T
MT
Novexel SA, Parc Biocitech, 102 route de Noisy, 93230 Romainville, France. mick.black@novexel.com
Hodgson
John
J
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects* / Q000235:genetics; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D001665:Binding Sites / Q000235:genetics; D024881:Drug Resistance, Bacterial / Q000187:drug effects* / Q000235:genetics; D016680:Genome, Bacterial / Q000235:genetics; D006801:Humans; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends
D000900:Anti-Bacterial Agents